ANNALS OF CLINICAL ONCOLOGY | ISSN 2674-3248 Available online at www.sciencerepository.org Science Repository *Correspondence to: Professor Gamal Shiha, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Dakahlia; Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; E-mail: g_shiha@hotmail.com © 2020 Gamal Shiha. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository. All rights reserved. http://dx.doi.org/10.31487/j.ACO.2020.03.01 Research Article Daclatasvir Plus Sofosbuvir With and Without Ribavirin for Previously Treated or Untreated Chronic HCV Infection Genotype 1, 2 and 4 in Togo Folly Anyovi 1 , Reham Soliman 6,8 , Lidaw Déassou Bawe 4,5 , Albert Théophane Yonli 1 , Simplice Karou 3 , Jacques Simpore 1,2 and Gamal Shiha 6,7* 1 Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR-SVT, Joseph KI-ZERBO University, Ouagadougou, Burkina Faso 2 Pietro Annigoni Biomolecular Research Center (CERBA), Ouagadougou, Burkina Faso 3 Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé, Togo 4 CHU Sylvanus Olympio, Service des Maladies Infectieuses et Tropicales, Togo 5 Faculté des sciences de la Santé, Université de Lomé, Togo 6 Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Dakahlia, Egypt 7 Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt 8 Tropical Medicine Department, Faculty of Medicine, Port Said University, Port Said, Egypt A R T I C L E I N F O Article history: Received: 10 October, 2020 Accepted: 20 October, 2020 Published: 5 November, 2020 Keywords: Génotype 1, 2, 4 hepatitis C sofosbuvir/daclatasvir patients naïfs Togo A B S T R A C T Background: Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection. We are using SOF-DCV combination for large scale treatment. Objectives: The aim of the current study was designed to investigate the efficacy and safety of sofosbuvir/daclatasvir, with or without ribavirin for previously treated or untreated in treatment of HCV genotype 1, 2 and 4, as well as their effect on the liver fibrosis. Methods: One hundred twenty-seven patients with chronic HCV infection were categorized into 2 groups. The group 1 comprised treatment naïve patients, with total serum bilirubin ≤ 1.2mg/10 -1 L, serum albumin ≥ 3,5g/ 10-1 L, ALAT ≥ 3N, ASAT≤ 2N and platelets count 150 x 10 9 /L. The group 2 included Peg-INF-alpha or sofosbuvir treatment-experienced patients or patients having at least 2 of the following characteristics: total bilirubin ≤ 1.2mg/10 -1 L, serum albumin ≥ 3,5g/ 10-1 L, ALAT ≥ 3N, ASAT ≤ 2N and platelets count 150 x 10 9 /L. The first group was treated with sofosbuvir/daclatasvir for 12 weeks except sofosbuvir treatment experienced patients, who were treated with sofosbuvir/daclatasvir + ribavirin for 24 weeks, with generic medications: DCV 60 mg plus SOF 400 mg ± ribavirin (RBV) within the treatment of hepatitis C virus infection. Efficacy and safety were assessed, and baseline factors associated with sustained virological response at post-treatment week 12 (SVR12) were explored. Results: Sustained virological response (SVR12), was 95,8% in group 1 and 93,8% in group 2. Such high efficacy was accompanied with tolerable adverse effects as well as with significant improvement in liver fibrosis. Conclusion: SOF plus DCV with or without ribavirin achieved high efficacy and safety in HCV genotypes 1,2 and 4 patients. Their effect was accompanied with attenuation of liver fibrosis. Further wider-scale studies are needed to evaluate the actual role of IL 18 polymorphism in treatment response with Sofosbuvir/Daclatasvir. © 2020 Gamal Shiha. Hosting by Science Repository. All rights reserved.